Table 4.
In vitro antiproliferative effects of selected compounds against cancer and normal cells
| ID | Cancer cells (IC50, μM) |
Normal cells (IC50, μM) |
||||
|---|---|---|---|---|---|---|
| HepG2 | HeLa | MDA-MB-231 | MCF-7 | MCF-10A | LO2 | |
| 12c | >20 | >20 | >20 | >20 | >50 | >50 |
| 12g | 10.86 ± 0.20 | 9.75 ± 0.21 | 8.88 ± 0.41 | 3.36 ± 0.17 | >50 | >50 |
| 12i | 8.25 ± 0.15 | 6.43 ± 0.18 | 3.81 ± 0.08 | 2.70 ± 0.13 | >50 | >50 |
| 12n | 7.66 ± 0.24 | 7.46 ± 0.07 | 13.57 ± 0.06 | 2.84 ± 0.08 | >50 | >50 |
| 12A | 5.63 ± 0.20 | 3.78 ± 0.15 | 4.51 ± 0.33 | 2.79 ± 0.15 | 185.7 ± 0.51 | 50.19 ± 0.35 |
| Imatinib | 28.08 ± 0.25 | 37.30 ± 0.22 | 28.19 ± 0.24 | 40.08 ± 0.35 | 39.37 ± 0.42 | 87.67 ± 0.31 |
| MOMIPP | 3.6 ± 0.045 | 5.2 ± 0.05 | 4.98 ± 0.11 | 4.5 ± 0.18 | >50 | >50 |
Cells were treated with indicated compounds for 48 h. Data are means ± SD of triplicate experiments.